SCHEMBL17570342

SCHEMBL17570342

CC(C)N(C)Cc1cccnc1Oc1ccc(C(=O)O)cc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ SRD5A2 P31213 1/20 0.42
▸ RXRA P19793 1/20 0.42
▸ NR4A2 P43354 1/20 0.42
▸ CARM1 Q86X55 1/20 0.42
▸ PRMT6 Q96LA8 1/20 0.42
▸ HTT P42858 2/20 0.41
▸ NPSR1 Q6W5P4 2/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.40
▸ MAPK8 P45983 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ NR1H4 Q96RI1 1/20 0.39
▸ ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16128021 0.87 KMT2A (0.51) KMT2AMEN1SRD5A2NR4A2HTT
SCHEMBL17570341 0.86 KMT2A (0.46) KMT2AMEN1HTTNPSR1L3MBTL1
SCHEMBL16128000 0.84 KMT2A (0.48) KMT2AMEN1SRD5A2HTTNPSR1
SCHEMBL17570339 0.81 CARM1 (0.49) KMT2AMEN1RXRANR4A2CARM1
SCHEMBL16128002 0.79 LOXL2 (0.52) KMT2AMEN1SRD5A2NR4A2HTT
SCHEMBL16128005 0.79 KMT2A (0.50) KMT2AMEN1SRD5A2CARM1PRMT6
SCHEMBL16128001 0.77 KMT2A (0.48) KMT2AMEN1CARM1PRMT6HTT
SCHEMBL25724248 0.74 KDM1A (0.41) KMT2AMEN1ALDH1A1
SCHEMBL16128020 0.73 KMT2A (0.50) KMT2AMEN1HTTNPSR1L3MBTL1
SCHEMBL17570337 0.73 TAS2R14 (0.48) SRD5A2RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180118735-A1 INHIBITORS OF LEUKOTRIENE A4 HYDROLASE GRA VENTURE FUND, LLC 2018-05-03 — — US disclosed
US-9822106-B2 Inhibitors of leukotriene A4 hydrolase CELTAXSYS, INC. (US) 2017-11-21 — — US disclosed
US-9822106-B2 Inhibitors of leukotriene A4 hydrolase CELTAXSYS, INC. (US) 2017-11-21 — — US disclosed
US-20160068522-A1 INHIBITORS OF LEUKOTRIENE A4 HYDROLASE CELLTAXIS, LLC 2016-03-10 — — US disclosed
US-20160068522-A1 INHIBITORS OF LEUKOTRIENE A4 HYDROLASE CELLTAXIS, LLC 2016-03-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068522-A1 INHIBITORS OF LEUKOTRIENE A4 HYDROLASE LTA4H, LTC4S, LTB4R KMT2A 2649/4885MEN1 3813/4885SRD5A2 851/4885
US-20180118735-A1 INHIBITORS OF LEUKOTRIENE A4 HYDROLASE LTA4H, LTC4S, LTB4R KMT2A 2649/4885MEN1 3813/4885SRD5A2 851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback